Funding Details
- Awarder
- SOSV
- Date Award
- May 13, 2024
- Vertical
- Therapeutics
- Funding URL
- View Funding Page
Company Info
- Founding Year
- Not provided in the memo
- Organizations Involved
- Not provided in the memo
- Founders
- Not provided in the memo
- Company Description
- ANA Therapeutics developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19. ANA Therapeutics was acquired by NeuroBo Pharmaceuticals in 2020.
- Market
- COVID-19 Treatment
- Location
-
United States
Links